This website is intended for UK healthcare professionals only


Forthcoming guidance
 
Published guidance
 
Select guidance type:
Select Clinical speciality:

Date: from to

Search



Title Type Clinical speciality   Expected date   Last updated date
Parkinson’s disease (update) NICE Clinical Guideline Central Nervous System Jun 2017 Apr 2017
Rhinitis management guidelines—update (British Society for Allergy and Clinical Immunology) Independent professional body guideline Eye, Ear, Nose & Throat Jun 2017 Jun 2017
British Association of Dermatologists' guidelines for biologic interventions for psoriasis (update) Independent professional body guideline Skin Jun 2017 Apr 2017
Guidelines on the management of sexual problems in men: the role of androgens–update (British Society for Sexual Medicine) Independent professional body guideline Obstetrics, Gynaecology & Urology Jun 2017 Jun 2017
Psoriasis (Primary Care Dermatology Society) Independent professional body guideline Skin Jun 2017 May 2017
Liraglutide for weight management NICE Evidence summary: new medicines Nutrition Jun 2017 -
Violence and aggression NICE Quality Standard Central Nervous System Jun 2017 Jun 2017
Violence and aggression NICE Quality Standard General Jun 2017 Jun 2017
Multimorbidity NICE Quality Standard General Jun 2017 Jun 2017
Liver disease NICE Quality Standard Endocrine Jun 2017 Jun 2017
Third molars (impacted)—prophylactic removal NICE Technology Appraisal General Jun 2017 Apr 2017
Neuroendocrine tumours (metastatic, unresectable)—everolimus, lutetium-177 and sunitinib NICE Technology Appraisal Malignant Disease Jun 2017 May 2017
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive)—lutetium-177 dotatate NICE Technology Appraisal Malignant Disease Jun 2017 Feb 2017
Leukaemia (chronic myeloid, acute lymphoblastic)—ponatinib (Iclusig) NICE Technology Appraisal Malignant Disease Jun 2017 Apr 2017
Pembrolizumab (Keytruda) for untreated PD-L1 positive metastatic non-small-cell lung cancer NICE Technology Appraisal Malignant Disease Jun 2017 Apr 2017
Etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism NICE Technology Appraisal Endocrine Jun 2017 Apr 2017
ivacaftor (Kalydeco®) All Wales Medicines Strategy Group appraisal Respiratory Jun 2017 Jun 2017
bevacizumab (Avastin®) All Wales Medicines Strategy Group appraisal Malignant Disease Jun 2017 Jun 2017
emtricitabine/tenofovir disoproxil fumarate (Truvada®) All Wales Medicines Strategy Group appraisal Infection Jun 2017 Jun 2017
vismodegib (Erivedge®) All Wales Medicines Strategy Group appraisal Malignant Disease Jun 2017 -


Choosing an appropriate inhaler device for the treatment of adults with asthma or COPD
Development Group: Usmani, Capstick, Chowhan, & Scullion.
This management algorithm was developed by a multidisciplinary expert panel: Usmani O et al with the support of a grant from Chiesi Ltd.

Management of asthma in adults over 65 years of age
Development group: Gruffydd-Jones, McArthur, Murphy, Russell & Wise.
This management algorithm was developed by a multidisciplinary expert panel: Gruffydd-Jones K et al with the support of a grant from Teva UK Limited.

Low back pain and sciatica in over 16s: assessment and management
National Institute for Health and Care Excellence

Chest pain of recent onset: assessment and diagnosis
National Institute for Health and Care Excellence

Choosing an appropriate inhaler device for the treatment of adults with asthma or COPD
Development Group: Usmani, Capstick, Chowhan, & Scullion.
This management algorithm was developed by a multidisciplinary expert panel: Usmani O et al with the support of a grant from Chiesi Ltd.

Low back pain and sciatica in over 16s: assessment and management
National Institute for Health and Care Excellence

Tinnitus guidance for GPs
British Tinnitus Association

Chest pain of recent onset: assessment and diagnosis
National Institute for Health and Care Excellence



Visit our NEW site!

Guidelines for Nurses provides current, credible summaries and feature articles developed especially for nurses.